Rosetta Genomics

Rosetta Genomics Overview



Rosetta Genomics is a leading developer of microRNA-based diagnostic tests and therapeutic tools. MicroRNAs (miRNAs) are a recently discovered group of short (21–23 nucleotides in length), non-coding genes which regulate the expression of other genes. MicroRNAs have also been shown to have varying expression levels across various pathological conditions, and offer a new class of highly sensitive and tissue specific biomarkers. MicroRNA-based diagnostics may offer physicians and patients an objective tool to accurately identify cancer, predict outcomes and help guide treatment.

Platform Technologies

Backed by a strong IP portfolio, Rosetta Genomics’ scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, women’s health and other indications. more

Development Engine

Based on our strong IP position which provides us access to hundreds of potential microRNAs biomarkers, our proprietary technologies, and our extensive network of collaborations, Rosetta Genomics has put in place a powerful development engine which can rapidly advance a wide range of microRNA-based tests. more

Advancing Cutting Edge Molecular Diagnostics

Rosetta Genomics’ proprietary technologies enable the development of a wide range of diagnostic tests for cancer and women’s health indications. Rosetta genomics believes that utilizing microRNAs as biomarkers in the development of next generation molecular diagnostics, presents several advantages over other currently used methods:

While many currently available cancer tests are largely qualitative and subjective, measuring microRNA expression levels in tissue samples offers quantitative, objective diagnosis.

Rosetta Genomics’ proprietary technologies enable microRNAs to be profiled with high sensitivity and specificity.

MicroRNAs are stable markers in many body fluids and tissue samples, making them an ideal platform for molecular diagnostics.

MicroRNAs have been found to be stable in Formalin Fixed Paraffin Embedded (FFPE) samples. FFPE samples, which are kept at room temperature, are the most widely used method for preserving tumor tissue. This will allow physicians to send samples for microRNA profiling via regular mail, without the need for temperature control.
more

MicroRNA-based Therapeutics

We seek to establish relationships with leading pharmaceutical companies and research institutions to develop microRNA-based products. In 2006, we joined forces with Isis Pharmaceuticals Inc. to develop a drug for liver cancer. With Isis, we have recently initiated in vivo studies on several microRNA targets, that, when inhibited, lead to a decrease in liver cancer cell growth. more

About the Rosetta Stone

Rosetta Genomics takes its name from the Rosetta Stone, a large ancient stone engraving discovered by Napoleon’s troops in 1799 in a small village on the Nile Delta. The Rosetta Stone includes sections of carved text presented in three different ancient scripts, including ancient Egyptian Hieroglyphics. For the first time, thanks to the Rosetta Stone, researchers were able to decipher ancient Egyptian Hieroglyphics, thereby opening the Ancient World to modern eyes.
As the Rosetta Stone helped to decode the meaning of ancient texts, so Rosetta Genomics is dedicated to unlocking the mysteries of microRNA, and more generally of the genetic code. We believe our efforts will help many others to understand this new “language” in healthcare and introduce a new generation of diagnostic and therapeutic products to improve human health.